{
  "id": 13731019,
  "title": "Neogen CEO Mikheal Nassif buys $6,034 in company stock",
  "url": "https://urgent.news/2026/10/11/neogen-ceo-mikheal-nassif-buys-6-034-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-11T14:16:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/neogen-ceo-mikheal-nassif-buys-6034-in-company-stock-93CH-4942715"
  },
  "original_language": "en",
  "account": "Neogen CEO Mikheal Nassif recently made a stock purchase of 505 shares, valued at $6,034, according to a recent SEC filing. The acquisition was executed on October 9, 2026, at a price of $11.95 per share, slightly above the current stock price of $11.85. This purchase comes as NEOG has seen a remarkable 96% return over the past year and a 70% gain year-to-date. Following the transaction, Mr. Nassif indirectly benefits from a beneficial ownership of 1,579 shares through his son. The reporting person has disclaimed beneficial ownership of these securities. Based on InvestingPro analysis, NEOG is currently considered overvalued relative to its Fair Value estimate and is listed as one of the platform's Most Overvalued stocks. Investors can access NEOG's comprehensive Pro Research Report for deeper insights.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock",
        "url": "https://urgent.news/2026/10/10/rapport-therapeutics-ceo-abraham-ceesay-sells-143-272-in-stock",
        "published": "2026-10-10T17:31:06.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}